NASDAQ:GTHXG1 Therapeutics Stock Price, Forecast & News

G1 Therapeutics' stock was trading at $14.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GTHX shares have increased by 37.1% and is now trading at $19.87. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for G1 Therapeutics.

G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for G1 Therapeutics.

G1 Therapeutics Inc (NASDAQ:GTHX) announced its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.82) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.98) by $0.16. View G1 Therapeutics' earnings history.

7 analysts have issued 12 month price objectives for G1 Therapeutics' stock. Their forecasts range from $23.00 to $82.00. On average, they anticipate G1 Therapeutics' share price to reach $61.50 in the next year. This suggests a possible upside of 209.5% from the stock's current price. View analysts' price targets for G1 Therapeutics.

Press coverage about GTHX stock has been trending negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. G1 Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutG1 Therapeutics.

G1 Therapeutics saw a decline in short interest in April. As of April 30th, there was short interest totaling 2,800,000 shares, a decline of 16.9% from the April 15th total of 3,370,000 shares. Based on an average daily trading volume, of 326,700 shares, the short-interest ratio is currently 8.6 days. Approximately 10.2% of the company's shares are short sold. View G1 Therapeutics' Current Options Chain.

Some companies that are related to G1 Therapeutics include Uniqure (QURE), Alkermes (ALKS), Taro Pharmaceutical Industries (TARO), Amarin (AMRN), Karuna Therapeutics (KRTX), Intercept Pharmaceuticals (ICPT), Insmed (INSM), Apellis Pharmaceuticals (APLS), Ra Pharmaceuticals (RARX), Turning Point Therapeutics (TPTX), Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), Pacira Biosciences (PCRX), TG Therapeutics (TGTX) and Ligand Pharmaceuticals (LGND). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Rite Aid (RAD), Alibaba Group (BABA), Johnson & Johnson (JNJ), Viking Therapeutics (VKTX), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Sorrento Therapeutics (SRNE), BioCryst Pharmaceuticals (BCRX) and Gilead Sciences (GILD).

(GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

G1 Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (9.86%), BlackRock Inc. (6.83%), JPMorgan Chase & Co. (4.49%), State Street Corp (3.64%), Geode Capital Management LLC (1.21%) and Deutsche Bank AG (1.15%). Company insiders that own G1 Therapeutics stock include Barclay A Phillips, Cynthia Schwalm, James S Hanson, Jay Strum, Jennifer K Moses, John Demaree, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View institutional ownership trends for G1 Therapeutics.

GTHX stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Burrage Capital Management LLC, UBS Group AG, Rhenman & Partners Asset Management AB, Alps Advisors Inc., State Street Corp, Virtus ETF Advisers LLC, and Legal & General Group Plc. View insider buying and selling activity for G1 Therapeutics.

GTHX stock was purchased by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Morgan Stanley, 361 Capital LLC, Two Sigma Investments LP, Federated Hermes Inc., Two Sigma Advisers LP, Geode Capital Management LLC, and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have bought G1 Therapeutics stock in the last two years include Cynthia Schwalm, James S Hanson, and John Demaree. View insider buying and selling activity for G1 Therapeutics.

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GTHX stock can currently be purchased for approximately $19.87.

G1 Therapeutics has a market capitalization of $749.89 million. The company earns $-122,450,000.00 in net income (profit) each year or ($3.27) on an earnings per share basis. G1 Therapeutics employs 84 workers across the globe.

The official website for G1 Therapeutics is www.g1therapeutics.com.

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835 or via email at [email protected]